Future Directions for GVHD

EP: 1.GVHD Pathophysiology

EP: 2.Differences Between Acute and Chronic GVHD and Risk Factors for GVHD

EP: 3.GVHD Prophylaxis and Patient Presentation

EP: 4.Chronic GVHD First-Line Therapy

EP: 5.Treatments for Steroid-Refractory cGVHD

EP: 6.Additional Therapy Options for Steroid-Refractory cGVHD

EP: 7.Adverse Events From cGVHD Therapies

Now Viewing

EP: 8.Future Directions for GVHD

Robert Zeiser, MD: After 4 decades of testing multiple approaches, we have now 3 approved drugs, which are ibrutinib, belumosudil, and ruxolitinib that were approved by the FDA for chronic graft-vs-host-disease [cGVHD] in the past 4 years, and ruxolitinib is also approved by the EMA [European Medicines Agency] for steroid refractory cGVHD. These developments are exciting, but there is still room for improvement. Oher exciting developments include regenerative approaches that are not immunosuppressive but rather target the regeneration, for example, of the damaged intestinal tract and what is also important is a better understanding of potential biomarkers and the involvement of the nonclassical GVHD.

Transcript edited for clarity.